Lumigan in Spain: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in Spain under the regulatory framework of AEMPS (Agencia Española de Medicamentos y Productos Sanitarios). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- Currency
- EUR
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in Spain
In Spain, most active medications require a prescription, with the SNS (national health system) covering a portion based on the patient's contribution group. Receta electrónica is widely used. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in Spain follows the standard rules of AEMPS (Agencia Española de Medicamentos y Productos Sanitarios).
Pharmacy dispensing
Spanish farmacias are typically independent and tightly regulated; the green cross signage marks every authorised pharmacy. Pharmacist consultation is normalised and often the first point of healthcare contact. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online sale of prescription medication is restricted in Spain — only physical farmacias and AEMPS-authorised online channels for non-prescription medication are permitted. Tele-prescribing has expanded since 2020. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in EUR
Retail pricing in Spain depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in Spain? ▾
In Spain, most active medications require a prescription, with the SNS (national health system) covering a portion based on the patient's contribution group. Receta electrónica is widely used. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of AEMPS (Agencia Española de Medicamentos y Productos Sanitarios).
Is generic Lumigan available in Spain? ▾
Authorised generics of Bimatoprost are typically available in Spain at a lower cost than branded Lumigan, with bioequivalence required by AEMPS (Agencia Española de Medicamentos y Productos Sanitarios). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in EUR? ▾
Prices in EUR vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Spain.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.